Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines

Published on Jan 1, 2021in Journal of Enzyme Inhibition and Medicinal Chemistry4.673
· DOI :10.1080/14756366.2020.1835883
Susanna Nencetti18
Estimated H-index: 18
(UniPi: University of Pisa),
Doretta Cuffaro5
Estimated H-index: 5
(UniPi: University of Pisa)
+ 11 AuthorsElisabetta Orlandini20
Estimated H-index: 20
(UniPi: University of Pisa)
Uveal melanoma (UM) represents an aggressive type of cancer and currently, there is no effective treatment for this metastatic disease. In the last years, histone deacetylase inhibitors (HDACIs) have been studied as a possible therapeutic treatment for UM, alone or in association with other chemotherapeutic agents. Here we synthesised a series of new HDACIs based on the SAHA scaffold bearing an (arylidene)aminoxy moiety. Their HDAC inhibitory activity was evaluated on isolated human HDAC1, 3, 6, and 8 by fluorometric assay and their binding mode in the catalytic site of HDACs was studied by molecular docking. The most promising hit was the quinoline derivative VS13, a nanomolar inhibitor of HDAC6, which exhibited a good antiproliferative effect on UM cell lines at micromolar concentration and a capability to modify the mRNA levels of HDAC target genes similar to that of SAHA.
Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used multi-omics approaches and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. Experimental Design: Mass spectrometry-based proteomics and RNA-Seq was used to identify the signaling pathways involved in the escape of uveal melanoma cells from MEK inhibitor therapy. Mechanistic studies were ...
33 CitationsSource
#1Sida Shen (UIC: University of Illinois at Chicago)H-Index: 11
#2Melissa Hadley (GW: George Washington University)H-Index: 6
Last. Alejandro Villagra (GW: George Washington University)H-Index: 29
view all 13 authors...
Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HDAC6-selective inhibitor containing the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker. A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordinatio...
26 CitationsSource
#1Michela CroceH-Index: 19
#2Silvano FerriniH-Index: 67
Last. Rosaria GangemiH-Index: 21
view all 4 authors...
Among Uveal Melanoma (UM) driver mutations, those involving GNAQ or GNA11 genes are the most frequent, while a minor fraction of tumors bears mutations in the PLCB4 or CYSLTR2 genes. Direct inhibition of constitutively active oncoproteins deriving from these mutations is still in its infancy in UM, whereas BRAFV600E-targeted therapy has obtained relevant results in cutaneous melanoma. However, UM driver mutations converge on common downstream signaling pathways such as PKC/MAPK, PI3K/AKT, and YA...
27 CitationsSource
Purpose: To determine the expression of histone deacetylase enzymes in uveal melanoma tumour cells. Procedures: This is an observational immunohistochemical study of 16 formalin-fixed, paraffin-embedded eyes enucleated for uveal melanoma between January 2001 and March 2002. Haematoxylin and eosin paraffin sections were reviewed for histopathological parameters according to the American Joint Committee on Cancer 7th edition. Sections were then immunohistochemically stained for histone deacetylase...
1 CitationsSource
#1Katharina Vögerl (LMU: Ludwig Maximilian University of Munich)H-Index: 2
#2Nghia Ong (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Franz Bracher (LMU: Ludwig Maximilian University of Munich)H-Index: 32
view all 16 authors...
The phenothiazine system was identified as a favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors. Here, we report the preparation and systematic variation of phenothiazines and their analogues containing a benzhydroxamic acid moiety as the zinc-binding group. We evaluated their ability to selectively inhibit HDAC6 by a recombinant HDAC enzyme assay, by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and b...
39 CitationsSource
#1Rekha Sangwan (Central Drug Research Institute)H-Index: 3
#2Remya Rajan (Central Drug Research Institute)H-Index: 2
Last. Pintu Kumar Mandal (AcSIR: Academy of Scientific and Innovative Research)H-Index: 9
view all 3 authors...
Abstract Even though one is moving towards the success in the discovery of efficient anti-cancer molecules, the drugs used in the treatment of various malignancies are found to possess toxicity and adverse reactivity in the human body that limit their use. The scientists all over the world are engaged in bringing up strategies that aim to develop small molecules that target the abnormal epigenetic factors. The discovery of the role of Histone deacetylases (HDACs) has promised to be a turning poi...
43 CitationsSource
#1Nicholas J. Porter (UPenn: University of Pennsylvania)H-Index: 11
#2Jeremy D. Osko (UPenn: University of Pennsylvania)H-Index: 7
Last. David W. Christianson (UPenn: University of Pennsylvania)H-Index: 92
view all 7 authors...
Four crystal structures are presented of histone deacetylase 6 (HDAC6) complexes with para-substituted phenylhydromaxamate inhibitors, including bulky peptoids. These structures provide insight regarding the design of capping groups that confer selectivity for binding to HDAC6, specifically with regard to interactions in a pocket formed by the L1 loop. Capping group interactions may also influence hydroxamate-Zn2+ coordination with monodentate or bidentate geometry.
40 CitationsSource
#1Marilita M Moschos (UoA: National and Kapodistrian University of Athens)H-Index: 26
#2Maria Dettoraki (UoA: National and Kapodistrian University of Athens)H-Index: 5
Last. Michael Tsatsos (UoI: University of Ioannina)H-Index: 1
view all 9 authors...
: Uveal melanoma is the most common intraocular malignancy in adults, representing approximately 3% of all melanoma cases. Despite progress in chemotherapy, radiation and surgical treatment options, the prognosis and survival rates remain poor. Acetylation of histone proteins causes transcription of genes involved in cell growth, DNA replication and progression of cell cycle. Overexpression of histone deacetylases occurs in a wide spectrum of malignancies. Histone deacetylase inhibitors block th...
17 CitationsSource
#1Amit Sharma (University of Bonn)H-Index: 9
#1Amit Sharma (University of Bonn)H-Index: 22
Last. Martina C. Herwig-Carl (University of Bonn)H-Index: 8
view all 6 authors...
Uveal melanoma (UM) is the most frequent primary intraocular tumor in Caucasian adults and is potentially fatal if metastases develop. While several prognostic genetic changes have been identified in UM, epigenetic influences are now getting closer attention. Recent technological advances have allowed to examine the human genome to a greater extent and have improved our understanding of several diseases including malignant tumors. In this context, there has been tremendous progress in the field ...
22 CitationsSource
#1Jessica Yang (CUMC: Columbia University Medical Center)H-Index: 5
#2Daniel K. Manson (CUMC: Columbia University Medical Center)H-Index: 3
Last. Richard D. Carvajal (CUMC: Columbia University Medical Center)H-Index: 61
view all 4 authors...
Uveal melanoma, a rare subset of melanoma, is the most common primary intraocular malignancy in adults. Despite effective primary therapy, nearly 50% of patients will develop metastatic disease. Ou...
102 CitationsSource
Cited By1
#1Yi Wang (University of Electronic Science and Technology of China)
#2Qiang Xie (University of Electronic Science and Technology of China)
Last. Bo Liu (Sichuan University)H-Index: 39
view all 8 authors...
Epigenetics mainly refers to covalent modifications to DNA or histones without affecting genomes, which ultimately lead to phenotypic changes in cells or organisms. Given the abundance of regulatory targets in epigenetic pathways and their pivotal roles in tumorigenesis and drug resistance, the development of epigenetic drugs holds a great promise for the current cancer therapy. However, lack of potent, selective, and clinically tractable small-molecule compounds makes the strategy to target can...